跳至主要内容
临床试验/NCT02175940
NCT02175940已完成不适用

Effect of Intravitreal Ranibizumab Injection on Aqueous Humor Concentrations of Vascular Endothelial Growth Factor and Pigment Epithelium-derived Factor in Patients With Myopic Choroidal Neovascularization.

Università degli Studi di Brescia1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2013年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
40
试验地点
1
主要终点
vascular endothelial growth factor (VEGF) aqueous levels

研究概览

简要总结

This was a prospective, case-control study investigating aqueous levels of VEGF and PEDF in eyes with mCNV treated with IVB.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • pathologic myopia, defined as spherical equivalent >6 diopters and axial length >26 mm
  • posterior pole myopic retinal changes (posterior staphyloma, chorioretinal atrophy, papillary crescent);
  • fluorescein angiography, indocyanine green angiography and optical coherence tomography detection of the subfoveal or juxtafoveal choroidal neovascularization
  • clear ocular media;

排除标准

  • previous treatment for choroidal neovascularization, including the previous intravitreal drug injection or PDT
  • presence of other maculopathy as diabetic retinopathy or retinal vascular occlusion
  • history of recent myocardial infarction or other thromboembolic events
  • ongoing uncontrolled hypertension or glaucoma
  • refractive media opacities
  • previous eye surgery

结局指标

主要结局

vascular endothelial growth factor (VEGF) aqueous levels

时间窗: 2 months

VEGF aqueous levels before and after intravitreal ranibizumab

pigment epithelium-derived factor (PEDF) aqueous levels

时间窗: 2 months

PEDF aqueous levels before and after intravitreal ranibizumab

次要结局

  • best-corrected visual acuity(2 months)
  • central retinal thickness(2 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Andrea Russo

MD, PhD Researcher

Università degli Studi di Brescia

研究点 (1)

Loading locations...

相似试验